- Home
- PDS vs AUPH Comparison
PDS vs AUPH Comparison
Compare PDS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDS
- AUPH
- Stock Information
- Founded
- PDS 1951
- AUPH 1993
- Country
- PDS Canada
- AUPH Canada
- Employees
- PDS N/A
- AUPH N/A
- Industry
- PDS
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- PDS
- AUPH Health Care
- Exchange
- PDS Nasdaq
- AUPH Nasdaq
- Market Cap
- PDS 649.5M
- AUPH 1.1B
- IPO Year
- PDS N/A
- AUPH 1999
- Fundamental
- Price
- PDS $47.13
- AUPH $8.77
- Analyst Decision
- PDS Buy
- AUPH Strong Buy
- Analyst Count
- PDS 1
- AUPH 2
- Target Price
- PDS $95.00
- AUPH $11.50
- AVG Volume (30 Days)
- PDS 118.8K
- AUPH 1.4M
- Earning Date
- PDS 07-29-2025
- AUPH 07-31-2025
- Dividend Yield
- PDS N/A
- AUPH N/A
- EPS Growth
- PDS N/A
- AUPH N/A
- EPS
- PDS 5.20
- AUPH 0.27
- Revenue
- PDS $1,301,611,298.00
- AUPH $247,295,000.00
- Revenue This Year
- PDS $1.35
- AUPH $12.15
- Revenue Next Year
- PDS $0.99
- AUPH $18.31
- P/E Ratio
- PDS $9.09
- AUPH $31.76
- Revenue Growth
- PDS N/A
- AUPH 29.20
- 52 Week Low
- PDS $36.20
- AUPH $5.20
- 52 Week High
- PDS $79.07
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- PDS 50.48
- AUPH 66.00
- Support Level
- PDS $45.97
- AUPH $7.71
- Resistance Level
- PDS $52.07
- AUPH $8.29
- Average True Range (ATR)
- PDS 1.46
- AUPH 0.25
- MACD
- PDS -0.52
- AUPH 0.03
- Stochastic Oscillator
- PDS 20.16
- AUPH 84.40
About PDS Precision Drilling Corporation
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.